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ABSTRACT
Complexes of 2-(4-thiazolyi)benzimidazole (thiabendazole, THBD) with Co(II), Ni(II), Cu(II) of
general formula ML2(NO3)2 H_O and complexes of Pd(II) and Pt(II) of general formula ML_CI, H20 have
been obtained and characterized by elemental analyses, IR and far IR spectroscopy and magnetic
measurements. The X-ray crystal structure of the copper(II) complex has been determined. The in vitro cell
proliferation inhibitory activity of these compounds was examined against human cancer cell lines A 549
(lung carcinoma), HCV-29 T (urinary bladder carcinoma), MCF-7 (breast cancer), T47D (breast cancer),
MES-SA (uterine carcinoma) and HL-60 (promyelocytic leukemia). Pt-THBD has been found to exhibit an
antileukemic activity of the HL-60 line cells matching that of an arbitrary criterion.
INTRODUCTION
Co-ordination compounds of metals have found increasing application for the treatment of many
diseases. For instance, they have been used as haematopoietic, antiphlogistic, bactericidal, antiarthiric and
antitumor drugs [1-3]. Studies of antitumor properties of platinum complexes have been triggered by the
detection by Rosenberg [4,5] of selective inhibition of cell division by cis- Pt(NH3)2CI2 and cis- Pt(NH3)zCI4
complexes. Their antitumor activity rests on the inhibition of DNA synthesis in the tumor cell, and the
structure of a compound being formed resembles that of cross-linked chains [6,7].
By now, platinum a containing antitumor drugs of a new generation, carboplatin, iproplatin and
spiroplatin, have gained widespread application [8]. Recently, studies of antitumor properties of the
complexes ofNi(|I), Mn(II), Co(II), Cu(II), Zn(II), Ru(II), Sn(II), Zr(II) and Ti(II) have been reported [9-11 ].
Many research workers have also studied the antitumor properties of complexes with azole ligands
[12-16]. In this connection it seemed worthwhile to study the activity of complexes of Co(II), Ni(1I), Cu(II),
Pd(II) and Pt(II) with a popular antiparasitic drug, 2-(4-thiazolyl)benzimidazole (thiabendazole, THBD;
Fig.l). The distribution of charge densities in the ligands was calculated by PM3 semiempirical methods
using a Hyper Chem 5.01 computer program for Windows 95 from Hypercube Inc. The purpose of this
contribution was to obtain an information about the composition of the complexes, co-ordination arrangement
of the central ion and to identify electron-donating atoms of the ligand as well as to determine the
antiproliferative activity of the complexes against cells of selected human tumor lines.
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Fig. 1. The charge density distribution ofTHBD
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MATERIALS AND METHODS
Reagents
2-(4-thiazolyl)benzimidazole (thiabendazole, THBD) was purchased from Sigma. The cobalt(II),
nickel(II) and copper(II) nitrates (POCh, Gliwice, Poland) were crystallized from redistilled water. The
preparation of PdCl_ and K2PdCI4 was described previously [17].
Physical measurements
Magnetic measurements at ambient temperature were run on a MSB-MKI (Sherwood Scientific Ltd.)
instrument. Elemental analyses were run on a Model 240 Perkin-Elmer CHN Analyzer.
The IR spectra (4000-250 cm"!) were taken on a Beckmann Model 4240 spectrophotometer in KBr
discs. The far-IR spectra (450-80 cm") were recorded on a DiGiLab FTS-60 spectrophotometer by applying
suspensions of the compounds in acetone onto the polyethylene window. Melting points were determined on
a Boetius apparatus. Magnetic measurements were accomplished on a MSB-MKI Instrument (Sherwood
Scientific Ltd) at ambient temperature. X-ray measurements were performed at room temperature using a
Kuma KM-4 four-circle diffractometer and the graphite monochromatic CuKo radiation 18].
The structures were solved by heavy-atom methods with SHELXS-86 and refined by the full-matrix least-
squares methods using SHELXL-93 with anisotropic parameters for all non-hydrogen atoms [19,20]. No
correction for absorption has been made. The positions of all hydrogen atoms were determined from the
differential Fourier synthesis [21,22]. The positions of the hydrogen atoms have not been refined. The atomic
scattering factors were those of neutral atoms incorporated in SHELXL-93 [20]. Details of the measurements
of the crystal data of the complexes (M-THBD) and the refinement parameters are listed in Table 2.
Preparation of the complexes
Complexes of composition MLz(NOs_)2 HzO with M Co(lI), Ni(lI) and C.u(!I)
To a solution of mmol of appropriate metal nitrate dissolved in 5.0 ml of redistilled water, a
solution of 2 mmol of THBD dissolved in 25.0 ml of hot (60-70C) absolute ethanol was added under
stirring. The solution was then left for crystallization. The precipitated complexes were filtered off,
recrystallized from hot ethanol, washed successively with acetone, diethyl ether, and dried in vacuo at 25C.
The yields were 70-80%.
Complexes of composition MLzC..CI,L_._2_O with M Pd(II) and Pt(II)
One mmol of PdCI2 was dissolved in 5.0 ml of hot (water bath) DMF and the solution was diluted
with 50.0 ml of acetone. Apart, mmol of K2PtCI4 was dissolved in 5.0 ml of redistilled water. Then, to each
solution, 2 mmol ofTHBD dissolved in 25.0 ml of hot (60-70C) absolute ethanol were added under stirring.
The solutions were left for crystallization, the complexes were filtered off, washed successively with hot
ethanol, acetone and diethyl ether, and dried in vacuo at 25C. The yields were 70-80%.
The antiproliferative.assay in vitro
Test solutions of the compounds (1 mg/ml) were freshly prepared for each test by dissolving them
either in 100 or 200 lal of DMSO + 900 or 800 lal of water pro injectione or, if soluble, in water only. Then
the compounds were diluted in a culture medium (described below) to reach final concentrations of 100, 10,
1, 0.1 and 0.01 tg/ml. Cells of the following human cancer lines were used: A 549 (non-small cell lung
carcinoma), MCF-7 and T47D (breast cancer), HCV-29 Y (bladder cancer), MES-SA (uterine cancer) and
HL-60 (promyelocitic leukemia). All lines were obtained from the American Type Culture Collection
(Rockville, Maryland, USA) and cultured in Cell Culture Collection of the Department of Tumor
Immunology, Institute of Immunology and Experimental Therapy, Wroclaw, Poland. Twenty four hours
before application of the tested compounds, the cells were placed in 96-well plates (Costar, USA) at density
of 104 cells per well in 100 l.tl. The cells were cultured in an opti- MEM medium supplemented with 2 mM
glutamine (Gibco, Warszawa), 50 l.tg/ml streptomycin (Polfa, Jelenia Gora). 50 U/ml penicillin (Polfa, Jelenia
Gora) and 5% fetal calf serum (Gibco, Grand Island, USA). The cells were cultured with the agents for 72 hrs
at 37C in a humid atmosphere saturated with 5% CO2.
The in vitro proliferation inhibition test, SRB (cell lines A-549, MCF-7, T47D, HCV-29 T and MES-
SA) was applied as described in Skehan’s paper [23].
Proliferation inhibition test, MTT (cell line HL-60)
Results of the tests were recorded by the colorimetric method from experiments carried out in flat-
bottomed 96-well plates. Cells suspended in 100t.tl of culture medium were placed in the wells, in a number
of 10
4 per well. After 24-hr under culture conditions, successive 100 t.tl portions of either the neat medium
(control of cell growth) or the medium containing a compound to be tested were added. The plates were
incubated under identical conditions over successive 72 hrs at 37C. After incubation, 20 1 a MTT (MTT
stands for 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma, St. Louis, MO; stock
solution: 5 mg/ml) solution was added. After a 4-hr incubation at 37C, 80 tl of a lysing buffer was added
consisting of 225 ml of dimethylformamide, 67.5 ml of sodium dodecyl sulfate (both purchased from Sigma,
St. Louis, MO) and 275 ml of distilled water. After successive 24 hrs of incubation at 37C, optical density of
the liquid contained in the wells was recorded on a RM Multiskan (Labsystem, Helsinki, Finnland), at 570
Flm.
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Zero adjustment of the photometer was accomplished by the so-called negative control, i.e. by the
liquid taken from the well containing the culture medium without cells. In each experiment, samples of
particular concentration of the compounds were applied in triplicate. The tests were likewise carried out in
triplicate.
RESULTS AND DISCUSSION
In order to determine the composition of the coordination compounds, elemental analyses (C, H, N,
metal) were run (Table 1). The results of magnetic measurements for the Co(II), Ni(II) and Cu(II) complexes
ofTHBD match the theoretical ones, while the Pd(II) and Pt(II) compounds turned out to be diamagnetic.
Table 1. Analytical and physical data for the complexes.
Complex
CoLi(No )i
NiL2(NO3)2 H20
(2)
CuL2(NO3)2’ H20
(3)
PdL2(CI2)2 H20
(4)
PtL2(Ci2)2 H20
15)
pink
blue
green
orange
yellow
Colour M.p.
(oc)
dec. 20’0
dec. 205
dec. 200
dec.> 230
dec.>235
Found (calc.)%
C
39.5
_(39.8)
39.7
(39.8)
39.3
(39.5)
40.0
(40.2)
34.7
134.9)_
2.8
(2.7)
2.9
(2.7)
2.4
(2.6)
2.5
(2.7)
2.3
12.3)
’18.4
(18.6)
18.3
(18.6)
18.1
(18.4)
14.0
(14.1)
12.0
(,,12.2)
M
9.6
(9.8)
10.0
(9.7)
10.1
(10.4)
17.6
(17.8)
28.7
128.4)
la (BM)
2.8
1.8
dia.
dia.
Fig.1 shows a schematic structure of the THBD molecule together with calculated electron densities
on optional electron-donating atoms. As seen, the optional electron-donating atom is the azomethine nitrogen
of the imidazole ring (-0.044). However, complexation through the nitrogen atom of the thiazole ring,
carrying negligible positive charge (+0.004) cannot be ruled out.
CRYSTALLOGRAPHY
Monocrystals needed for the determination of the crystal structure could only be obtained with the
Cu-THBD compound.
Details of the measurements for complex (3) crystal data together with the refinement parameters are
shown in Table 2. As seen in Fig. 2, the Cu(II) ion in coordinated by lone electron pairs of the azomethine
nitrogen atoms of the imidazole and thiazole rings and, in addition, by one of the oxygen atoms of the nitrate
group to form a pentacoordinate structure. Such a coordination mode is in excellent agreement with the
calculated electron densities (Fig.l).
Small differences in bond lenghts in the immediate surrounding of the central ion can be explained in
terms of hydrogen bonds between one of the hydrogen atoms of water molecule and an oxygen atom of the
coordinated nitrato group as well as between the oxygen atom of the non- coordinated nitrate group and the
hydrogen atoms of the benzimidazole moiety. A chelating effect cannot be excluded, as well.
Infrared spectroscopy
The IR spectrum (4000-400 cm
l range) of the complex resembles that of the non-coordinated ligand. Certain
differences are noted over the stretching vibration range of the system of conjugate C=C and C=N double
bonds of the compounds.
Table 3 lists absorption bands characteristic of thiabendazole and its complexes. As seen, the largest
displacements due to complexation relative to thiabendazole are noted for the C=N and C=C bands.
The C-N bands are only little shifted, whereas those due to C-S remain unchanged. Remarkable are
bands due to stretching and deformation vibrations of the water molecules as well as of coordinated and non-
coordinated NO3 groups [24,25].
These are due to the bending and stretching vibrations of the metal-oxygen bonds (for the Co(II),
Ni(II) and Cu(II) complexes) and of the metal-nitrogen bonds (for the Pd(II) and Pt(ll) compounds).
Absorption bands at 291,296, 315, 350 and 347 cm are likely to be due to vibrations of the dative metal-
nitrogen linkages for the complexes of Co(If), Ni(II), Cu(II), Pd(ll) and Pt(ll), whereas those at 437, 437 and
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438 cm" are due to M-O linkages in the complexes of Co(II), Ni(II) and Cu(II), respectively, with
thiabendazole [26,27].
Fig.2. Molecular structure and atom labeling scheme for complex (3).
Table 2. Crystal data and structure refinement for Cu(THBD)2(NO3): HeO
EmPirical formula’
Formul weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal size
2 0 range
Range of h, k,
Reflection collected/unique
Refinement method
Data[l>2 (I)]/Parameters
Goodness-of-fit on F
Final R indices [I>2 (I)]
R indices (all data)
Largest diff. Peak and hole
Weighting scheme
Diffractometer
Programs used
Deposition number
Co i16u N’’ 0’7 S’2
608.0
293 (2) K
0.71073/
monoc[inic
P 2/c
a 7.924 (2)
b 27.022 (5)
c 11.275 (2)
13 103.87 (3)
2343.8 (8) A
4
1.72 Mg/m
1.172 mm"
1236
0.15 x 0.15 x 0.20 mm
3.5-27.0
-7/10,-34/32,-14/13
15203 5046 [R (int) 0.0208 Full- matrix least squares on F
4451 407
1.06
Rt 0.037, w Re 0.086
R 0.042, w Re 0.089
1.74 and-0.87 e. fi-3
w=[/[a2(Fo2)+ (0.05p)2+ 0.00P] where P= (Fo2+
2Fc)/3
Kuma KM-4
SHELXL-93, SHELXL-86
CCDC167906
Selected most important bond length and angles are as follows: Cu-N(21)-l.960(2), Cu-N(11)-1.973(2), Cu-
N(13)-2.077(2), Cu-O(1)- 2.2226(19) ., N(21)-Cu-N(11)-176.67(8), N(21)-Cu-N(13)-95.53(8), N(I 1)-Cu-
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N(13)-81.66(8), N(21)-Cu-N(23)-80.01(8), N(11)-Cu-N(23)-103.21(8), N(13)-Cu- N(23)-133.89(8), N(21)-
Cu-O(1)-89.18(8), N(11)-Cu-O(1)-91.94(8), N(13)-Cu- O(1)- 141.57(7), N(23)-Cu-O(1)-84.51(7).
On the basis of these findings, it can be speculated that the copper(II) compound of THBD has a
pentacoordinate structure. A similar structure can be assigned to the cobalt(II) and nickel(II) complexes,
whilst those of palladium(II) and platinum(II) form planar square structures.
Table 3. Characteristic frequencies in cm
"1 of the ligand and its complexes.
vH,O HO C=N C=C C-N C-S NO,
.Ligand 1580 i420 1245 750
l(Co) 3400 1650 1620 1435 1248 750 1335
2 (Ni) 3400 1650 1600 1440 1247 750 1330
.3 (Cu) 3500 1630 1560 1400 1246 750 1330
4 (Pd) 3500 1625 1600 1440 1250 750
5 (Pt) 3500 1630 1600 1430 1250 750
1380
1390
1420
Antiproliferative assay
Results of the assay, presented as IDs0 (this denotes a dose of a compound inducing the proliferation
inhibition of 50 per cent of the cancer cell population), carried out for cells of particular cancer cell lines, are
shown in Table 4.
The adopted activity criterion for the compounds in the in vitro screening was an IDs0 level not
exceeding 4 lag/ml [28]. No compound satisfied that criterion.
As seen in Table 4, only the Pt(II)-THBD complex exhibited activity matching that set by the
criterion in an assay against the HL-60 leukemia cells and those of urinary bladder carcinoma HCV-29 T
cells.
Table 4. In vivo cytotoxic activity of the thiabendazole complexes against human cancer cell lines.
Compound Cell iine/IDs0 [tg/ml]
T47D MCF7 MEs-sA HL-60 A549
Pd THBD neg neg neg 61.0 _
2.0
Co THBD 61.2 _+ 1.3 neg 87.7 + 1’1 23.2 _
1.0
Cu THBD 30.7 1.1 34.5 _.+ 1.0 34.5 + 1.0 24.6 _
1.2
Ni THBD neg neg n.eg 56.0 + 2.3
Pt THBD 29.0 _+ 1.3 39.2 _+ 1.2 37.8 _+ 1.0 5.8 _+ 1.6
Cis[latin 2.1 +__ 1.8 3.2 +_. 1.2 1.4 +_ 1.0 0.2 +_ 1.5
HCV-29T
neg neg
49.0 + 1.0 11.0 + 4.0
4.0 + 1.0 0.7 +__ 0.01
Of the cancer cells tested, only the leukemia cells have been found to be sensitive to all the
coordination compounds tested. Besides, the copper(lI) and platinum(II) complexes of THBD
exhibited the ability to inhibit proliferation of cells of all the cancer lines tested. Again, the Co(II)-
THBD compound inhibited proliferation of some cell lines only, notably those of T47D, MES-SA
and HL-60, whereas the palladium(lI) and nickel(II) complexes exhibited only a low activity
against the HL-60 cells.
To sum up, as far as the in vivo antiproliferative activity assay conducted is concerned, it
can be concluded that further studied should be focused on the HL-60 leukemia cells.
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